Attached files

file filename
EX-99.1 - EX-99.1 - MYMETICS CORPl40686exv99w1.htm
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 13, 2010
Mymetics Corporation
(Exact name of registrant as specified in its charter)
Delaware   000-25132   25-1741849
(State of other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)
Route de la Corniche 4    
1066 Epalinges, Switzerland   NA
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: +011 41 21 653 45 35
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 8.01. Other Events.
     On September 13, 2010, the registrant (“Mymetics”) issued a press release regarding the partial funding by the National Institutes of Health (“NIH”) of a new preclinical trial at the University of California, Davis. The study will be led by Professor Christopher J. Miller of the California National Primate Research Center to test the effectiveness of a candidate HIV vaccine in a nonhuman primate model. A copy of the press release is furnished as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
     99.1 Press Release dated September 13, 2010



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: September 13, 2010  MYMETICS CORPORATION
  By:   /s/ Jacques-François Martin    
    Jacques-François Martin   
    President and Chief Executive Officer